Loading...

THC Biomed Intl

CNSX:THC
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
THC
CNSX
CA$36M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

THC Biomed Intl Ltd. produces and sells medical marijuana in Canada. The last earnings update was 83 days ago. More info.


Add to Portfolio Compare Print
  • THC Biomed Intl has significant price volatility in the past 3 months.
THC Share Price and Events
7 Day Returns
-5.8%
CNSX:THC
-2.6%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-81.2%
CNSX:THC
-9.9%
CA Pharmaceuticals
-2%
CA Market
THC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
THC Biomed Intl (THC) -5.8% -9.3% -33.8% -81.2% 113% 444.4%
CA Pharmaceuticals -2.6% -13% -21.2% -9.9% 615.8% 445.1%
CA Market 1.3% -0.1% 0.2% -2% 12% 3.1%
1 Year Return vs Industry and Market
  • THC underperformed the Pharmaceuticals industry which returned -9.9% over the past year.
  • THC underperformed the Market in Canada which returned -2% over the past year.
Price Volatility
THC
Industry
5yr Volatility vs Market

THC Value

 Is THC Biomed Intl undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for THC Biomed Intl. This is due to cash flow or dividend data being unavailable. The share price is CA$0.245.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for THC Biomed Intl's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are THC Biomed Intl's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:THC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in CAD CA$-0.06
CNSX:THC Share Price ** CNSX (2019-06-19) in CAD CA$0.25
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 21.1x
Canada Market PE Ratio Median Figure of 543 Publicly-Listed Companies 15.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of THC Biomed Intl.

CNSX:THC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:THC Share Price ÷ EPS (both in CAD)

= 0.25 ÷ -0.06

-4.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • THC Biomed Intl is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • THC Biomed Intl is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does THC Biomed Intl's expected growth come at a high price?
Raw Data
CNSX:THC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.16x
Canada Market PEG Ratio Median Figure of 248 Publicly-Listed Companies 1.15x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for THC Biomed Intl, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on THC Biomed Intl's assets?
Raw Data
CNSX:THC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in CAD CA$0.11
CNSX:THC Share Price * CNSX (2019-06-19) in CAD CA$0.25
Canada Pharmaceuticals Industry PB Ratio Median Figure of 144 Publicly-Listed Pharmaceuticals Companies 2.59x
Canada Market PB Ratio Median Figure of 2,417 Publicly-Listed Companies 1.41x
CNSX:THC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:THC Share Price ÷ Book Value per Share (both in CAD)

= 0.25 ÷ 0.11

2.18x

* Primary Listing of THC Biomed Intl.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • THC Biomed Intl is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess THC Biomed Intl's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. THC Biomed Intl has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

THC Future Performance

 How is THC Biomed Intl expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as THC Biomed Intl has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
89.2%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is THC Biomed Intl expected to grow at an attractive rate?
  • Unable to compare THC Biomed Intl's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare THC Biomed Intl's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare THC Biomed Intl's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:THC Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 89.2%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 54.8%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:THC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:THC Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-01-31 1 -3 -7
2018-10-31 1 -3 -12
2018-07-31 1 -2 -12
2018-04-30 1 -2 -10
2018-01-31 1 -1 -11
2017-10-31 0 -1 -1
2017-07-31 0 -1 -1
2017-04-30 0 -1 0
2017-01-31 0 -1 1
2016-10-31 -2 1
2016-07-31 -1 -1
2016-04-30 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if THC Biomed Intl is high growth as no earnings estimate data is available.
  • Unable to determine if THC Biomed Intl is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:THC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from THC Biomed Intl Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:THC Past Financials Data
Date (Data in CAD Millions) EPS *
2019-01-31 -0.06
2018-10-31 -0.10
2018-07-31 -0.11
2018-04-30 -0.09
2018-01-31 -0.10
2017-10-31 -0.01
2017-07-31 -0.01
2017-04-30 0.00
2017-01-31 0.01
2016-10-31 0.01
2016-07-31 -0.01
2016-04-30 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if THC Biomed Intl will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of THC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. THC Biomed Intl's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. THC Biomed Intl's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess THC Biomed Intl's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
THC Biomed Intl has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

THC Past Performance

  How has THC Biomed Intl performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare THC Biomed Intl's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • THC Biomed Intl does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare THC Biomed Intl's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare THC Biomed Intl's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
THC Biomed Intl's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from THC Biomed Intl Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:THC Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 1.10 -6.91 4.24
2018-10-31 0.93 -11.54 3.35
2018-07-31 0.93 -12.46 2.81
2018-04-30 0.78 -10.18 2.50
2018-01-31 0.64 -10.83 2.12
2017-10-31 0.34 -1.36 1.76
2017-07-31 0.06 -0.60 1.30
2017-04-30 0.04 0.28 0.82
2017-01-31 0.00 0.76 0.87
2016-10-31 0.70 0.86
2016-07-31 -0.54 0.89
2016-04-30 -1.65 2.08 -0.04
2016-01-31 -1.81 2.20 -0.03
2015-10-31 -3.18 2.11 -0.02
2015-07-31 -3.06 1.96
2015-04-30 -2.00 0.80 0.06
2015-01-31 -1.63 0.47 0.06
2014-10-31 -0.36 0.28 0.05
2014-07-31 -0.22 0.15 0.04

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if THC Biomed Intl has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if THC Biomed Intl has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if THC Biomed Intl improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess THC Biomed Intl's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
THC Biomed Intl has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

THC Health

 How is THC Biomed Intl's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up THC Biomed Intl's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • THC Biomed Intl is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • THC Biomed Intl's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of THC Biomed Intl's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 7.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from THC Biomed Intl Company Filings, last reported 4 months ago.

CNSX:THC Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 14.15 1.40 0.85
2018-10-31 16.30 1.55 1.82
2018-07-31 12.21 1.65 2.01
2018-04-30 13.00 1.41 4.52
2018-01-31 1.18 1.52 4.36
2017-10-31 3.79 1.48 0.72
2017-07-31 1.98 1.83 0.02
2017-04-30 1.88 0.68 0.03
2017-01-31 2.62 0.60 0.21
2016-10-31 2.45 0.85 0.73
2016-07-31 0.35 0.78 0.11
2016-04-30 0.34 0.66 0.08
2016-01-31 0.10 0.65 0.05
2015-10-31 -1.53 0.99 0.01
2015-07-31 -1.51 0.95 0.05
2015-04-30 -0.38 0.97 0.01
2015-01-31 0.03 0.95 0.16
2014-10-31 -0.11 0.40
2014-07-31 -0.11 0.40
  • THC Biomed Intl's level of debt (9.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if THC Biomed Intl's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • THC Biomed Intl has less than a year of cash runway based on current free cash flow.
  • THC Biomed Intl has less than a year of cash runway if free cash flow continues to grow at historical rates of 81.8% each year.
X
Financial health checks
We assess THC Biomed Intl's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. THC Biomed Intl has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

THC Dividends

 What is THC Biomed Intl's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from THC Biomed Intl dividends.
If you bought CA$2,000 of THC Biomed Intl shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate THC Biomed Intl's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate THC Biomed Intl's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:THC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 335 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as THC Biomed Intl has not reported any payouts.
  • Unable to verify if THC Biomed Intl's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of THC Biomed Intl's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as THC Biomed Intl has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess THC Biomed Intl's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can THC Biomed Intl afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. THC Biomed Intl has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

THC Management

 What is the CEO of THC Biomed Intl's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Miller
COMPENSATION CA$62,400
CEO Bio

Mr. John Miller serves as Chief Executive Officer and President of THC Biomed Intl Ltd. and its Director since June 3, 2014.

CEO Compensation
  • John's compensation has been consistent with company performance over the past year, both up more than 20%.
  • John's remuneration is lower than average for companies of similar size in Canada.
Management Team

John Miller

TITLE
Chief Executive Officer
COMPENSATION
CA$62K

Jung Hee

TITLE
Co-Founder
COMPENSATION
CA$62K

Damien Reynolds

TITLE
Chief Capital Markets Officer
TENURE
3.9 yrs

Dianne Szigety

TITLE
Corporate Secretary
AGE
64
TENURE
3.5 yrs
Board of Directors Tenure

Average tenure of the THC Biomed Intl board of directors in years:

4.5
Average Tenure
  • The tenure for the THC Biomed Intl board of directors is about average.
Board of Directors

John Miller

TITLE
Chief Executive Officer
COMPENSATION
CA$62K
TENURE
5 yrs

Jung Hee

TITLE
Co-Founder
COMPENSATION
CA$62K
TENURE
5 yrs

Don Shaxon

TITLE
Member of Advisory Board
TENURE
3.9 yrs

Jason Springett

TITLE
Member of Advisory Board
TENURE
3.9 yrs
Who owns this company?
Recent Insider Trading
  • THC Biomed Intl insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
05. Jun 19 Buy John Miller Individual 31. May 19 31. May 19 25,000 CA$0.30 CA$7,453
04. Jun 19 Buy John Miller Individual 30. May 19 30. May 19 31,500 CA$0.29 CA$9,135
03. Jun 19 Buy John Miller Individual 28. May 19 29. May 19 170,500 CA$0.29 CA$48,054
01. Jun 19 Buy John Miller Individual 27. May 19 27. May 19 50,000 CA$0.29 CA$14,087
29. May 19 Buy John Miller Individual 24. May 19 24. May 19 77,500 CA$0.29 CA$22,002
28. May 19 Buy John Miller Individual 23. May 19 23. May 19 145,500 CA$0.30 CA$42,270
02. Apr 19 Sell Jung Hee Individual 28. Mar 19 28. Mar 19 -63,500 CA$0.35 CA$-21,487
01. Apr 19 Sell Jung Hee Individual 27. Mar 19 27. Mar 19 -130,000 CA$0.35 CA$-45,617
03. Apr 19 Sell Jung Hee Individual 29. Mar 19 29. Mar 19 -250,000 CA$0.35 CA$-84,600
30. Mar 19 Sell Jung Hee Individual 25. Mar 19 25. Mar 19 -200,000 CA$0.36 CA$-71,580
22. Mar 19 Sell Jung Hee Individual 18. Mar 19 18. Mar 19 -60,500 CA$0.40 CA$-24,200
27. Mar 19 Sell Jung Hee Individual 22. Mar 19 22. Mar 19 -170,000 CA$0.38 CA$-63,600
26. Mar 19 Sell Jung Hee Individual 21. Mar 19 21. Mar 19 -50,000 CA$0.38 CA$-19,250
25. Mar 19 Sell Jung Hee Individual 20. Mar 19 20. Mar 19 -138,500 CA$0.40 CA$-54,208
19. Mar 19 Sell Jung Hee Individual 14. Mar 19 14. Mar 19 -385,000 CA$0.40 CA$-154,000
16. Mar 19 Sell Jung Hee Individual 11. Mar 19 12. Mar 19 -425,000 CA$0.42 CA$-171,934
20. Jan 19 Sell Jung Hee Individual 15. Jan 19 15. Jan 19 -20,000 CA$0.50 CA$-10,000
X
Management checks
We assess THC Biomed Intl's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. THC Biomed Intl has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

THC News

Simply Wall St News

What Kind Of Shareholders Own THC Biomed Intl Ltd. (CNSX:THC)?

With a market capitalization of CA$41m, THC Biomed Intl is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for THC Biomed Intl CNSX:THC Ownership Summary, May 29th 2019 What Does The Institutional Ownership Tell Us About THC Biomed Intl? … Insider Ownership Of THC Biomed Intl The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Read This Before Buying THC Biomed Intl Ltd. (CNSX:THC) Shares

So shareholders might well want to know whether insiders have been buying or selling shares in THC Biomed Intl Ltd. … THC Biomed Intl Insider Transactions Over The Last Year. … Over the last year, we can see that the biggest insider sale was by Co-Founder Jung Hee for CA$976k worth of shares, at about CA$1.00 per share

Simply Wall St -

Are THC Biomed Intl Ltd's (CNSX:THC) Interest Costs Too High?

While small-cap stocks, such as THC Biomed Intl Ltd (CNSX:THC) with its market cap of CA$56m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

How Financially Strong Is THC Biomed Intl Ltd (CNSX:THC)?

THC Biomed Intl Ltd (CNSX:THC) is a small-cap stock with a market capitalization of CA$153.75m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Pharmaceuticals companies,

Simply Wall St -

THC Company Info

Description

THC Biomed Intl Ltd. produces and sells medical marijuana in Canada. It also conducts research and development of the products and services related to cannabis for medical purposes. The company was founded in 2012 and is based in Kelowna, Canada.

Details
Name: THC Biomed Intl Ltd.
THC
Exchange: CNSX
Founded: 2012
CA$35,862,943
146,379,363
Website: http://www.thcbiomed.com
Address: THC Biomed Intl Ltd.
Towne Centre,
PO Box 20033,
Kelowna,
British Columbia, V1Y 9H2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX THC Common Shares Canadian National Stock Exchange CA CAD 02. Sep 1988
DB TFHD Common Shares Deutsche Boerse AG DE EUR 02. Sep 1988
DB TFHD COM NPV Deutsche Boerse AG DE EUR 30. Apr 2015
Number of employees
Current staff
Staff numbers
27
THC Biomed Intl employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/20 00:57
End of day share price update: 2019/06/19 00:00
Last earnings filing: 2019/03/29
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.